Expanded response letter to "Hemodialysis dose and frequency should be considered in the subgroup analysis"

Li-Chun Lin¹, Chung-An Wang², Vin-Cent Wu^{3

4

5}

Affiliations

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² College of Medicine, Taipei Medical University, Taipei, Taiwan.
³ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. q91421028@ntu.edu.tw.
⁴ Primary aldosteronism center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. q91421028@ntu.edu.tw.
⁵ National Taiwan University Hospital Study Group of Acute Renal Failure and Taiwan Consortium for Acute Kidney Injury and Renal Diseases, Taipei, Taiwan. q91421028@ntu.edu.tw.

Comment

Li-Chun Lin et al. Cardiovasc Diabetol. 2024.

. 2024 Nov 19;23(1):417.

doi: 10.1186/s12933-024-02483-w.

Li-Chun Lin¹, Chung-An Wang², Vin-Cent Wu^{3

4

5}

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² College of Medicine, Taipei Medical University, Taipei, Taiwan.
³ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. q91421028@ntu.edu.tw.
⁴ Primary aldosteronism center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. q91421028@ntu.edu.tw.
⁵ National Taiwan University Hospital Study Group of Acute Renal Failure and Taiwan Consortium for Acute Kidney Injury and Renal Diseases, Taipei, Taiwan. q91421028@ntu.edu.tw.

No abstract available

Conflict of interest statement

Declarations Competing interests The authors declare no competing interests.

Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis.
Wang CA, Lin LC, Chen JY, Wang WJ, Wu VC. Wang CA, et al. Cardiovasc Diabetol. 2024 Sep 3;23(1):327. doi: 10.1186/s12933-024-02424-7. Cardiovasc Diabetol. 2024. PMID: 39227933 Free PMC article.

1. Wang C-A, Lin L-C, Chen J-Y, Wang W-J, Wu V-C. Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis. Cardiovasc Diabetol. 2024;23(1):327. - PMC - PubMed
1. TriNetX Data Dictionary. Stony Brook Medicine. Available at: Stony Brook Guide.